| 1. |
- Andrén, Lennart, 1946, et al.
(author)
-
Diltiazem in hypertensive patients with type II diabetes mellitus.
- 1988
-
In: The American journal of cardiology. - : Elsevier BV. - 0002-9149. ; 62:11
-
Journal article (peer-reviewed)abstract
- Twenty-three patients with essential hypertension and diabetes mellitus type II were treated with the calcium antagonist diltiazem (120 to 180 mg twice daily). The mean dose was 307 mg/day. The study was a double-blind, placebo-controlled, crossover design. All measurements were performed 12 to 14 hours after drug intake. Blood pressure, heart rate and forearm blood flow were measured noninvasively. Platelet function was studied by measuring adenosine diphosphate-induced platelet aggregation and the platelet specific proteins, beta thromboglobulin and platelet factor 4. Thromboxane B2 formation in serum and the plasma concentration of diltiazem and its metabolites N-demethyldiltiazem, deacetyldiltiazem and N-demethyldeacetyldiltiazem were measured both during placebo and diltiazem treatment. Diabetic control was evaluated by following HbA1C, fasting blood glucose and urinary glucose. Diltiazem reduced both systolic and diastolic (supine and standing) blood pressure significantly. Forearm blood flow was significantly increased by 32%, p less than 0.05. Supine heart rate decreased significantly, while no such change was seen in the standing position. No significant changes were observed in platelet function during diltiazem treatment. There was no relation between the observed blood pressure reduction and the plasma concentration of diltiazem or its metabolites. A positive correlation between the change in heart rate and the metabolite N-demethyldeacetyldiltiazem was observed (r = 0.647, p = 0.005). Three patients were excluded during diltiazem treatment (skin exanthema, headache and atrial fibrillation) and 1 during placebo treatment (angina pectoris). No negative effect on diabetes control was observed. Thus, diltiazem could be used for treatment of hypertension in diabetic patients.
|
|
| 2. |
|
|
| 3. |
- Engel, J A, et al.
(author)
-
Biochemical and behavioral evidence for an interaction between ethanol and calcium channel antagonists.
- 1988
-
In: Journal of neural transmission. ; 74:3, s. 181-93
-
Journal article (peer-reviewed)abstract
- In the present series of experiments we have studied the effects of the dihydropyridine calcium channel antagonist nifedipine on ethanol-induced changes in behavior and dopamine (DA) release and metabolism. The locomotor-stimulatory effect of low doses of ethanol (2.5 g/kg) was antagonized by nifedipine, whereas ethanol-induced sedation observed after higher doses (4.5 g/kg) was potentiated. Biochemical studies indicated that ethanol enhanced the metabolism and release of DA in the striatum and the DA-rich limbic regions measured by post mortem analyses of DA-metabolites by HPLC with electrochemical detection and by in vivo voltammetry in anaesthetized rats, respectively. Pretreatment with nifedipine antagonized the stimulatory effects of ethanol on the DA-system. Nifedipine reduced the preference for ethanol, estimated by the relative intake of ethanol (6% v/v) and water in a free-choice situation, suggesting an influence of nifedipine not only on the stimulatory but also on the positive reinforcing effects of ethanol. The present results suggest that the locomotor-stimulatory and positive reinforcing effects of ethanol as well as its enhancing effect on dopaminergic activity may involve an enhancement of calcium mediated mechanisms.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Nilsson, B, et al.
(author)
-
Production of mouse monoclonal antibodies that detect distinct neoantigenic epitopes on bound C3b and iC3b but not on the corresponding soluble fragments.
- 1987
-
In: Molecular Immunology. - 0161-5890 .- 1872-9142. ; 24:5, s. 487-494
-
Journal article (peer-reviewed)abstract
- Polyclonal antibodies raised in rabbits against sodium dodecyl sulphate (SDS)-denatured and reduced human complement factor C3 have in recent studies been shown to lack any reactivity towards native C3 but to react with antigens distinctly expressed by SDS-denatured C3 (C3(D) antigens). These antigens are also neoantigens specific for physiologically bound C3 and appear to be involved in the interaction of C3 with other complement components. The present investigation deals with production of mouse monoclonal antibodies against C3(D) antigens. To accomplish this two different immunization and screening procedures employing C3 preparations of known C3(D) expression were tested. From each group 14 clones were randomly selected and the reactivity of these and of a control group of 14 additional monoclonal anti-human C3 antibody preparations raised against native soluble C3 and C3b, was investigated in ELISA and immunoblotting. The procedure which employed denatured reduced C3 as both immunogen as well as screening antigen was shown to be superior for obtaining anti-C3(D) antibodies. Altogether 16 clones producing antibodies against C3(D) antigens were found. All of them bound to the C3 alpha-chain, 14 to C3c and one to C3d, and eight monoclonal antibodies specific for neoantigens of C3(D) type on bound C3b and/or iC3b were obtained. The majority of these detected neoantigenic epitopes in the 25,000 N-terminal fragment of the C3 alpha-chain specifically exposed by bound iC3b, but one monoclonal antibody was specific for the 36,000 C-terminal alpha-chain fragment and for both bound C3b and iC3b.
|
|
| 7. |
- Sahlin, Nils-Eric, et al.
(author)
-
The role of second-order probabilities in decision making
- 1983
-
In: Analysing and Aiding Decision Processes. - 0166-4115. - 9780444865229 ; 14, s. 455-467
-
Book chapter (peer-reviewed)abstract
- The importance, legitimacy and role of second-order probabilities are discussed. Two descriptive models of the use of second-order probabilities in decisions are presented. The results of two empirical studies of the effects of second-order probabilities upon the rank orderings of bets are summarized briefly. The bets were of three basic types and involved a wide variety of first- and second-order probabilities as subjectively assessed by the subjects. Support was obtained for the assumption that the majority of subjects make use of the one model or the other. It is suggested that greater attention should be paid to second-order probabilities, both from a normative and descriptive standpoint.
|
|
| 8. |
- Schalén, C, et al.
(author)
-
Demonstration of separate receptors for human IgA and IgG in group A streptococci type 4. Separation of the solubilized receptors from group- and type-specific antigens, lipoteichoic acid and peptidoglycan
- 1980
-
In: Acta Pathologica et Microbiologica Scandinavica. Section C, Immunology. - : Wiley. - 0304-1328. ; 88:2, s. 77-82
-
Journal article (peer-reviewed)abstract
- The alkaline extract of group A streptococci type 4 was separated by electrophoresis and diffused against 27 normal human sera. One of the precipitates appeared with 85% of the sear. Addition of purified IgA myeloma protein or sera containing IgA M-components to the extract changed the electrophoretic mobility of the precipitate anodically. Purified IgG Fc-fragments or sera containing IgG M-component did not affect the mobility of the precipitate. It was concluded that this precipitate contained the streptococcal receptor for human IgA. A non-precipitating IgG Fc-receptor, with agglutinating capacity for cells coated with human IgG1 but not IgG3, was localized by preparative electrophoresis to the same electrophoretic region as the IgA receptor. The mobility of the IgG receptor remained unaltered on addition of IgA myeloma protein permitting a separation of the two receptors by preparative electrophoresis. The receptors were distinct from the group specific carbohydrate, peptidoglycan and lipoteicholic acid. No M antigen or opacity factor were demonstrated in the extract.
|
|
| 9. |
|
|
| 10. |
|
|
